Jaron Mark, MD, gynecologic oncology fellow at Roswell Park Comprehensive Cancer Center, discusses findings from a restrictive protocol that limited the number of opioids prescribed after gynecologic surgeries. Patients looked at in this trial had undergone ambulatory or minimally invasive procedures.
Jaron Mark, MD, gynecologic oncology fellow at Roswell Park Comprehensive Cancer Center, discusses findings from a restrictive protocol that limited the number of opioids prescribed after gynecologic surgeries. Patients looked at in this trial had undergone ambulatory or minimally invasive procedures.
An analysis of patients that had the same surgeries a year prior to this protocol was used as the control group. Jaron said based off of those results, there was a dramatic decrease in opioids dispensed at a rate of 97%. The average amount of tablets given to patients was reduced from 31 tablets to 0.9 tablets per patient.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More